Press

Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas

Mar 18 • 2 min read

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced participation in the upcoming Public Ventures Discovery Day on March 19, 2024 in Dallas, TX. Doug Drysdale, Chief Executive Officer of Cybin will participate in a…

Cybin Inc. – Announces Oversubscribed Private Placement of U.S. $150 Million

Mar 14 • 5 min read

TORONTO – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) (‘Cybin’ or the ‘Company’), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, is pleased to announce a proposed private placement of 348,837,210 common shares in the capital of the Company at a price of U.S.$0.43 per Common Share representing…

Clearmind Medicine Obtains Clearance for Its Psychedelic- Based Alcoholism Clinical Trial

Mar 14 • 3 min read

Clearmind Medicine Inc. announced that it has received approval from the Israeli Ministry of Health to commence its phase I/IIa clinical trial for alcohol use disorder (AUD) patients using the company’s proprietary MEAI-based (5-methoxy-2-aminoindane) CMND-100 oral capsule. The approval, previously announced on February 23, 2024, allows Clearmind to start its pioneering clinical trial. The clinical…

ATMA CENA Psychedelic Healthcare Solutions Opens Psychedelic-Assisted Therapy Clinic in Calgary and Provides Update of its Clinic Network

Mar 14 • 5 min read

CALGARY, AB, March 14, 2024 /CNW/ – ATMA CENA Psychedelic Healthcare Solutions (PHS) is a collaboration of ATMA Journey Centers Inc. (“ATMA”), Cena Life Inc., and partners across Canada to advance and expand access to psychedelic-assisted therapy (PaT) through the establishment of a clinic network. ATMA CENA PHS is pleased to announce commencement of the Calgary Clinic operations and its new location in Edmonton. The London and Toronto, Ontario clinic locations…

Cybin Inc. Announces Positive End-Of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design

Mar 14 • 4 min read

Cybin Inc. announced a positive End-of-Phase 2 meeting with the FDA for CYB003, its deuterated psilocybin analog for the adjunctive treatment of Major Depressive Disorder (MDD). This program will be the first ever adjunctive Phase 3 deuterated psilocybin analog depression study globally and follows the successful completion of the Company?s Phase 2 study in MDD…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435